Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Shares (Diluted, Weighted) for the year ending March 31, 2024: 831,049,444

Roivant Sciences Ltd. Shares (Diluted, Weighted) is 831,049,444 for the year ending March 31, 2024, a 0.00% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Roivant Sciences Ltd. Shares (Diluted, Weighted) for the year ending March 31, 2024 was 831,049,444, a 16.59% change year over year.
Roivant Sciences Ltd. Shares (Diluted, Weighted) for the year ending March 31, 2023 was 712,791,115, a 6.43% change year over year.
Roivant Sciences Ltd. Shares (Diluted, Weighted) for the year ending March 31, 2022 was 669,753,458, a -2.20% change year over year.
Roivant Sciences Ltd. Shares (Diluted, Weighted) for the year ending March 31, 2021 was 684,789,169, a 217.98% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years